FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:2346-2348 June 2, 2005 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Martin, M. PubMed Citation

Chemotherapy, an integral component of adjuvant treatment for women with resected node-positive breast cancer, improves disease-free and overall survival in many patients. Older regimens include such combinations as cyclophosphamide, methotrexate, and fluorouracil; doxorubicin and cyclophosphamide; fluorouracil, doxorubicin, and cyclophosphamide given in various doses and according to various schedules; and fluorouracil, epirubicin, and cyclophosphamide, among others. Standards of care continue to evolve, owing to the availability of new drugs and data from innovative clinical trials that have tested different combinations of existing and new agents.

The taxanes (docetaxel and paclitaxel) have emerged as potent agents for the adjuvant treatment of early . . . [Full Text of this Article]

Source Information

From the Mayo Clinic, Jacksonville, Fla.

This article has been cited by other articles:

• Lenihan, D. J., Esteva, F. J. (2008). Multidisciplinary Strategy for Managing Cardiovascular Risks When Treating Patients with Early Breast Cancer. The Oncologist 13: 1224-1234 [Abstract] [Full Text]  
• von Minckwitz, G., Kummel, S., du Bois, A., Eiermann, W., Eidtmann, H., Gerber, B., Hilfrich, J., Huober, J., Costa, S. D., Jackisch, C., Grasshoff, S.-T., Vescia, S., Skacel, T., Loibl, S., Mehta, K. M., Kaufmann, M., On behalf of the German Breast Group, (2008). Pegfilgrastim {+/-} ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol 19: 292-298 [Abstract] [Full Text]  
• Martin, M., Lluch, A., Segui, M. A., Ruiz, A., Ramos, M., Adrover, E., Rodriguez-Lescure, A., Grosse, R., Calvo, L., Fernandez-Chacon, C., Roset, M., Anton, A., Isla, D., del Prado, P. M., Iglesias, L., Zaluski, J., Arcusa, A., Lopez-Vega, J. M., Munoz, M., Mel, J. R. (2006). Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 17: 1205-1212 [Abstract] [Full Text]